Roivant In Talks To Sell Stomach Drug To Roche In Deal Valued At More Than $7B
Portfolio Pulse from Charles Gross
Roivant Sciences is reportedly in discussions to sell its stomach drug to Roche in a deal that could be valued at over $7 billion, according to the Wall Street Journal.
July 13, 2023 | 9:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche is in talks to acquire a stomach drug from Roivant Sciences, potentially expanding its portfolio. The deal could be valued at over $7 billion.
The acquisition of the stomach drug from Roivant Sciences could potentially expand Roche's portfolio and strengthen its position in the pharmaceutical market. This could positively impact Roche's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100